Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Acromegaly - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The Acromegaly ...

Acromegaly is characterized by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and affects quality of life and mortality. Oczyesa was submitted in a hybrid application ...

The second presentation on symptom variability in acromegaly shows the significant disease burden that patients on long-acting injectable somatostatin analogs can experience. Additionally ...

His editorial clients include the Atlanta Business Chronicle and Advisors magazine. Most dental insurers delay coverage of expensive treatments for at least six to 12 months. This prevents people ...

Paltusotine aims to provide a new once-daily oral treatment option for acromegaly patients, with regulatory reviews underway in both the U.S. and EU. Crinetics is also sponsoring a Product Theater ...

Now, a study published in the Journal of Endocrinological Investigation offers a new hypothesis: the giants of Mont’e Prama could have been inspired by people with acromegaly, a medical condition that ...

We are on-track with the FDA review and preparations for the anticipated launch of paltusotine for acromegaly, while also moving forward with multiple late-stage studies. We are excited to unveil ...

A boy with no allergies or medical conditions other than asthma died May 6 while under sedation for a dental procedure at a practice in Oklahoma, according to multiple news stories published on May 8.

A child died Tuesday during a dental procedure in Edmond, according to the Edmond Police Department. Authorities said the child went into cardiac arrest either while under anesthesia or while ...

I can’t say enough good things about this practice. I have severe dental anxiety and every single person I encountered during my two visits did their best to make me feel at ease. I was greeted ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).